Aktienanalyse zu Molecular Partners AG (MOLN)MOLNMolecular Partners AG

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. It operates in the Healthcare sector.

Molecular Partners AG (MOLN) is currently trading at $3.48, significantly below its 52-week high of $5.36, indicating potential upside. However, the stock has a low RSI of 35.332, suggesting it is oversold, but it has also shown a 5-day decline of 3.06%. The forward P/E ratio is 1.7027, indicating potential for growth, but the company is currently facing substantial losses with a net income of -13,144,000 CHF in Q1 2026. The main risk is its negative earnings trend, with EPS expected at -0.46 for the last quarter, which could further pressure the stock price.